The contracts valued at approximately GBP330,000 in total, are for regulatory consultancy and follow on from the first contract for regulatory support signed in January this year.
The regulatory consultancy relates to three GMP manufacturing contracts for specific antibodies currently being delivered by Angel.
Gordon Sherriff, chief operating officer of Angel, said: “This demonstrates our strategy to offer integrated services spanning process development, scale-up and GMP manufacturing from pre-clinical to product for commercial scale, and complemented by regulatory consultancy expertise is proving successful.”
Sergey Tarasov of Material Medica R&D department, said: “We are very pleased to award a further three consultancy contracts to Angel, our established manufacturer for Materia Medica’s antibody based products.”